Bevantolol

Bevantolol
Clinical data

AHFS/Drugs.com	International Drug Names
Routes of administration	Oral
ATC code	C07AB06 (WHO)
Legal status
Legal status	unapproved, never marketed
Identifiers
IUPAC name (RS)-[2-(3,4-dimethoxyphenyl)ethyl][2-hydroxy-3-(3-methylphenoxy)propyl]amine
CAS Number	59170-23-9^Y
PubChem (CID)	2372
DrugBank	DB01295^Y
ChemSpider	2282^Y
UNII	34ZXW6ZV21^Y
ChEBI	CHEBI:238698^Y
ChEMBL	CHEMBL314010^Y
Chemical and physical data
Formula	C₂₀H₂₇NO₄
Molar mass	345.43 g/mol
3D model (Jmol)	Interactive image
Chirality	Racemic mixture
SMILES O(c1ccc(cc1OC)CCNCC(O)COc2cc(ccc2)C)C
InChI InChI=1S/C20H27NO4/c1-15-5-4-6-18(11-15)25-14-17(22)13-21-10-9-16-7-8-19(23-2)20(12-16)24-3/h4-8,11-12,17,21-22H,9-10,13-14H2,1-3H3^Y Key:HXLAFSUPPDYFEO-UHFFFAOYSA-N^Y
(verify)

Bevantolol (INN) was a drug candidate for angina and hypertension that acted as both a beta blocker and a calcium channel blocker.^[1]^[2] It was discovered and developed by Warner-Lambert^[3] but in January 1989 the company announced that it had withdrawn the New Drug Application; the company's chairman said: "Who needs the 30th beta blocker?"^[4] As of 2016 it wasn't marketed in the US, UK, or Europe and the authors of a Cochrane review could find no product monograph for it.^[5]

References

↑ Frishman, WH; Goldberg, RJ; Benfield, P (January 1988). "Bevantolol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension and angina pectoris.". Drugs. 35 (1): 1–21. PMID 2894292.
↑ Vaughan Williams, EM (July 1987). "Bevantolol: a beta-1 adrenoceptor antagonist with unique additional actions.". Journal of clinical pharmacology. 27 (7): 450–60. PMID 2888789.
↑ McPherson, Edwin M. (2007). Pharmaceutical Manufacturing Encyclopedia. (3rd ed. ed.). Burlington: Elsevier. pp. 618–619. ISBN 9780815518563. CS1 maint: Extra text (link)
↑ "Warner-Lambert Pipeline Narrowed to 40 Active Research Compounds". Pink Sheet. 30 January 1989.
↑ Wong, GW; Boyda, HN; Wright, JM (10 March 2016). "Blood pressure lowering efficacy of beta-1 selective beta blockers for primary hypertension.". The Cochrane database of systematic reviews. 3: CD007451. PMID 26961574.

Beta blockers (C07)

β, non-selective	Alprenolol Bopindolol Bupranolol Carteolol Cloranolol Mepindolol Nadolol Oxprenolol Penbutolol Pindolol/Iodopindolol Propranolol Sotalol Tertatolol Timolol

β₁-selective	Acebutolol Atenolol Betaxolol Bevantolol Bisoprolol Celiprolol Epanolol Esmolol Metoprolol Nebivolol Practolol S-Atenolol Talinolol

β₂-selective	Butaxamine

α₁- + β-selective	Arotinolol Carvedilol Labetalol

^#WHO-EM ^‡Withdrawn from market Clinical trials: ^†Phase III ^§Never to phase III

This article is issued from Wikipedia - version of the 11/27/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.